1 Β· ED Quick Pathway
Suspected opioid withdrawal
β
ABCDE + vital signs + mental status
β
Confirm opioid exposure and assess COWS (Clinical Opiate Withdrawal Scale) β section 4
β
Identify the opioid, dose, route and time of last use
β
Ask specifically about fentanyl exposure β changes induction timing and precipitated-withdrawal risk (section 6β7)
β
Exclude opioid intoxication and other serious causes of the presentation (sepsis, serotonin syndrome, sympathomimetic toxicity, thyrotoxicosis, alcohol/benzodiazepine withdrawal)
β
Is the patient in objective withdrawal? β No β supportive treatment only; reassess when withdrawal develops; do not give routine buprenorphine/naloxone induction while the patient is not in adequate withdrawal
β
Is the patient in objective withdrawal? β Yes β buprenorphine/naloxone induction: initial 4 mg/1 mg SL
β
Reassess after 30β60 minutes
β
Significant withdrawal persists? β Yes β give additional 4β8 mg/1β2 mg SL SL
β
Reassess again after 30β60 minutes; continue titration according to symptoms
β
Typical ED total during induction: 8β16 mg buprenorphine β some patients, particularly those with high opioid tolerance or fentanyl exposure, may require higher doses
2 Β· Why Does Opioid Withdrawal Occur?
- Chronic opioid exposure causes: tolerance and physical dependence
- Abrupt reduction or cessation causes: reduced opioid-receptor stimulation β rebound autonomic/noradrenergic activity β the withdrawal syndrome
- Common precipitants: prescription ran out Β· abrupt discontinuation Β· reduced dose Β· unable to obtain illicit opioids Β· deliberate attempt to stop opioid use Β· hospitalisation or a procedure interrupting usual opioid therapy
- Onset and duration depend on the opioid's half-life: short-acting opioids (e.g. heroin, immediate-release oxycodone) β onset 6β12 h, peak 1β3 days; long-acting opioids (e.g. methadone, extended-release formulations) β onset 24β48 h, more prolonged course. Fentanyl behaves unpredictably because of its high potency and tissue accumulation with repeated use.
3 Β· Clinical Features of Opioid Withdrawal
- Autonomic: tachycardia, hypertension, sweating, yawning, rhinorrhoea, lacrimation
- Gastrointestinal: nausea, vomiting, diarrhoea, abdominal cramping
- Musculoskeletal: myalgia, arthralgia, bone aches, restlessness, tremor
- Neuropsychiatric: anxiety, irritability, insomnia, drug craving, dysphoria
- Other signs: piloerection ('gooseflesh'), mydriasis (dilated pupils)
- Not typically caused by opioid withdrawal alone: fever, seizures, significant haemodynamic instability, or depressed consciousness β actively look for an alternative or additional cause if these are present
4 Β· COWS β Clinical Opiate Withdrawal Scale
- Purpose: an 11-item observer-rated scale used to objectively grade withdrawal severity and to decide when buprenorphine induction is safe to start
- Items scored (0 up to 4β5 each): resting pulse rate Β· sweating Β· restlessness Β· pupil size Β· bone/joint aches Β· rhinorrhoea/lacrimation Β· GI upset (nausea, vomiting, diarrhoea) Β· tremor Β· yawning Β· anxiety/irritability Β· gooseflesh skin
- Total score interpretation: 5β12 mild Β· 13β24 moderate Β· 25β36 moderately severe Β· >36 severe
- Practical threshold for starting buprenorphine/naloxone: most ED induction pathways use a COWS of roughly 8 or above (objective, observable withdrawal) as the trigger to give the first dose β a patient who only reports craving or subjective discomfort without objective signs is not yet in withdrawal
- Reassess COWS before each subsequent dose to guide titration (section 6)
5 Β· Before Induction β Assessment & Precautions
- Confirm objective withdrawal using COWS (section 4) before giving the first dose β the single most important step in avoiding precipitated withdrawal
- Time since last opioid use matters: short-acting opioids (heroin, oxycodone, morphine) β wait until at least 6β12 hours since last use and objective withdrawal is present; methadone β generally wait longer (often 24β36 hours) given its long half-life; fentanyl β unpredictable and often requires a longer wait and/or a more cautious, lower starting dose because of tissue accumulation and a higher risk of precipitated withdrawal
- Ask specifically about fentanyl exposure β common in the current illicit opioid supply, often unrecognised by the patient, and the main driver of precipitated withdrawal after an otherwise 'standard' induction
- Relative cautions: significant hepatic impairment (buprenorphine is hepatically metabolised β use with caution and consider lower doses); concurrent benzodiazepine, alcohol or other sedative use (additive sedation risk β caution and monitoring, not an absolute contraindication); pregnancy (involve obstetrics/addiction-medicine support β see section 10); altered mental status or significant respiratory depression from other causes (treat/exclude first)
- Confirm the patient wants to start treatment and understands what buprenorphine/naloxone induction involves, including the possibility of transient discomfort during titration
- Document baseline vital signs, mental status, COWS score and time of last opioid use before the first dose
6 Β· Buprenorphine/Naloxone Induction Protocol
- Confirm objective withdrawal (COWS generally β₯ 8) before the first dose
- Initial dose: 4 mg/1 mg SL (buprenorphine/naloxone), allowed to dissolve fully under the tongue
- Reassess at 30β60 minutes: repeat vital signs and COWS
- If significant withdrawal persists: give an additional 4β8 mg/1β2 mg SL
- Reassess again at 30β60 minutes and continue titrating according to symptoms and COWS
- Typical total ED dose during induction: 8β16 mg buprenorphine component; higher total doses may be required in patients with high opioid tolerance or significant fentanyl exposure
- Between doses: continue to exclude an alternative cause for ongoing symptoms (section 3) rather than assuming every symptom is under-dosed withdrawal
- If symptoms resolve or become mild/tolerable: further dosing is usually unnecessary that visit β move to monitoring and disposition planning (section 11)
7 Β· Precipitated Withdrawal
- What it is: buprenorphine is a high-affinity partial opioid agonist β if given before a full agonist has sufficiently cleared the receptor (i.e. before the patient is in adequate objective withdrawal), it can displace the full agonist and trigger an abrupt, severe withdrawal reaction
- Recognition: sudden, marked worsening of withdrawal symptoms within roughly 30β90 minutes of a buprenorphine/naloxone dose, often more severe than the patient's baseline withdrawal β look for a sharp rise in COWS rather than a gradual one
- Highest risk: dosing too early relative to last use, methadone or other long-acting opioid use, and significant fentanyl exposure
- Management is mainly supportive: reassure the patient this is a recognised, self-limited reaction; treat symptoms (section 9: antiemetics, antidiarrhoeals, analgesia, clonidine if available); maintain hydration
- Continuing buprenorphine titration (rather than stopping) often helps once enough has been given to more fully occupy the receptor β further small doses can be given and titrated as in section 6 if the patient remains in significant withdrawal, guided by reassessment
- Full-agonist opioids are not the preferred rescue and will themselves be displaced/blocked at the occupied receptor β they are not typically effective for reversing precipitated withdrawal and are unlikely to help
- Escalate for senior/addiction-medicine input if symptoms are severe, prolonged, or the diagnosis is uncertain
8 Β· Low-Dose ('Micro-Dosing') Induction β Alternative Approach
- Principle: very small, gradually increasing doses of buprenorphine are started while the patient continues their usual full-agonist opioid, avoiding the need for the patient to be in withdrawal before starting β this reduces precipitated-withdrawal risk
- When it may be considered: significant fentanyl exposure, high opioid tolerance, a patient unwilling or unable to tolerate a period of withdrawal, or a failed standard induction with precipitated withdrawal
- Practical note for the ED: this approach is typically carried out over several days and is better suited to an inpatient admission or a structured outpatient/bridge pathway with follow-up than to a single ED visit β involve addiction-medicine support early if this approach is being considered
- Do not attempt an unsupervised rapid version of this approach without a clear local protocol and follow-up plan
9 Β· Symptomatic / Adjunct Treatment
- Autonomic symptoms (if buprenorphine unavailable, declined, or as an adjunct): clonidine (alpha-2 agonist) β monitor blood pressure and heart rate; avoid or use with caution in hypotension
- Nausea/vomiting: standard antiemetics (e.g. ondansetron)
- Diarrhoea: loperamide
- Myalgia/arthralgia: paracetamol and/or NSAIDs if not contraindicated
- Abdominal cramping: an antispasmodic if needed
- Anxiety/insomnia: non-benzodiazepine options are preferred where possible (e.g. hydroxyzine); use sedatives cautiously given additive respiratory-depression risk with any opioid on board
- These are adjuncts, not substitutes for buprenorphine/naloxone induction in a patient who wants to start treatment and is in objective withdrawal
10 Β· Special Populations
- Pregnancy: opioid withdrawal in pregnancy can precipitate fetal distress and preterm labour β this is not a 'wait and see' situation. Involve obstetrics and addiction-medicine support early; buprenorphine-based treatment is generally continued/started with specialist input rather than withheld
- Hepatic impairment: buprenorphine is hepatically metabolised β use caution and consider lower doses in significant impairment; monitor closely
- Renal impairment: no major dose adjustment typically required, but monitor closely as for any opioid-related treatment
- Elderly/frail patients: start at the lower end of the dosing range and titrate more slowly
- Concurrent benzodiazepine, alcohol or other sedative use: increased risk of sedation and respiratory depression β this is a reason for caution and closer monitoring, not an automatic contraindication to treating withdrawal
- Adolescents: involve paediatric/adolescent and addiction-medicine specialists β dosing and consent considerations differ from adults
11 Β· Monitoring & Disposition
- After each dose: observe for sedation, respiratory rate and oxygen saturation, and reassess COWS before deciding on further dosing
- Typical ED observation period: at least 1β2 hours after the last dose, longer if sedation, precipitated withdrawal, or polysubstance use is a concern
- Criteria to consider for discharge: vital signs stable, no excess sedation, withdrawal symptoms adequately controlled, patient alert and able to understand discharge/safety information, no unresolved medical concern requiring admission
- Consider admission or extended observation for: precipitated withdrawal that has not settled, significant polysubstance intoxication/withdrawal, unstable vital signs, pregnancy with ongoing concern, or significant medical/psychiatric comorbidity
- This is also an opportunity to address any acute medical issue that may have interrupted opioid therapy or precipitated this presentation
12 Β· Discharge Planning & Harm Reduction
- Arrange a bridge prescription or supply of buprenorphine/naloxone where local pathways allow, with clear instructions on continuing home dosing
- Arrange follow-up with an addiction-medicine service or outpatient prescriber as soon as possible, ideally within a few days
- Provide take-home naloxone and overdose-prevention education for the patient (and household/support person where possible) β tolerance drops quickly after any period of reduced use, raising overdose risk if the patient returns to previous doses of illicit opioids
- Harm-reduction counselling: avoid using alone, avoid combining opioids with other sedatives/alcohol, start low and go slow if any non-prescribed opioid use occurs, and know the signs of overdose
- Safety-netting advice: do not drive or operate machinery if drowsy; return to the ED for worsening sedation, confusion, or breathing difficulty; safe storage of take-home medication, especially away from children
- Document the induction (times, doses, COWS scores), discharge medication supplied, and the follow-up plan clearly
13 Β· Safety Warnings
- Do not give buprenorphine/naloxone to a patient who is not in objective withdrawal β this risks precipitating a severe withdrawal reaction (section 7)
- Ask specifically about fentanyl exposure in every patient β it is common, often unrecognised, and changes both timing and precipitated-withdrawal risk
- Buprenorphine has a ceiling effect on respiratory depression but is not risk-free β sedation risk increases substantially when combined with benzodiazepines, alcohol or other sedatives
- A full-agonist opioid is not an effective or reliable rescue for precipitated withdrawal β manage supportively and by continuing buprenorphine titration instead (section 7)
- Opioid withdrawal in pregnancy is not benign β involve obstetric and addiction-medicine support early rather than withholding treatment (section 10)
- Always provide take-home naloxone at discharge β tolerance falls quickly after any period of reduced opioid use, and overdose risk rises sharply if the patient returns to a previous illicit-opioid dose
- This protocol is a clinical reference to be used alongside local policy, clinician judgement and current guidance β it does not replace specialist addiction-medicine input for complex cases